The prevalence of immune-related adverse events (irAE) from chemoimmunotherapy was recorded.#Of 240 patients identified: 86 received KEYNOTE-522 and 154 received control. The frequency of pCR was significantly higher in KEYNOTE versus the control cohort, 59.3% and 33.1%, respectively (p= 0.001)...
We report the case of a patient with synchronous TNBC and HER2-amplified breast cancer successfully treated to pathologic complete response by time of mastectomy with a modified hybrid KN522 and TCHP neoadjuvant regimen. To our knowledge, this is the first report of a pathologic complete response ...
“Together with the efficacy and safety findings of KEYNOTE-522, these PRO results support neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab as an effective standard-of-care treatment regimen in this setting, without meaningful impact on health-related quality of...
2、Gianni L, et al. Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. ESMO Congress 2023, LBA19 3、Loi S, et al...
Additional prospective study with larger sample size is needed to understand whether all patients benefit from completing the Keynote 522 regimen.All RegimensChemo RegimensPembrolizumab%, Number of Patients (NoP) with Complications12.26% (N=13)54.72% (N=58)16.98% (N=18)NoP Completed Full Dose ...
Here we report the case of a patient diagnosed with clearly demarcated, pathologically heterogenous triple negative breast cancer (TNBC) and HER2+ breast cancer that was treated with a hybrid chemoimmunotherapy regimen combining elements of Keynote-522 and a standard HER2-directed neoadjuvant regimen,...